Abstract
Recent data have proposed that transcription of the KAI1 metastasis suppressor gene is directly mediated by p53 and that loss of KAI1 expression in advanced prostate cancer is simply due to loss of p53 function after mutation. To investigate this possibility, we have examined KAI1 mRNA (by in situ hybridisation) and p53 protein expression (by immunohistochemistry) as an indicator of wildtype or mutant p53, in a series of 77 paraffin-embedded prostate tissue samples, including post-mortem normal prostates (2), benign prostatic hyperplasia (10), localised cancer (grades 4–6, 25; grades 7–9, 21) and prostate-derived bony metastases (19). Overall, we confirmed that expression of KAI1 mRNA decreased from normal tissue, through localised cancer to bony metastases (P=0.055, tending to significance), while levels of p53 staining significantly increased with cancer progression (P=0.046). These were consistent with the possibility that loss of p53 function might be responsible for loss of KAI1 mRNA. However, by close examination of KAI1 and p53 in adjacent tissue sections, we found no correlation between decreased levels of KAI1 mRNA and overexpression of p53 protein (P=0.497). In addition, high levels of KAI1 mRNA could be identified in samples irrespective of p53 staining. Our data suggest that mutation of p53 is independent of the loss of KAI1 mRNA, and do not support a role for p53 in regulating the expression of KAI1.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dong JT et al. KAI1, a metastasis suppressor for prostate cancer on chromosome 11 p11.2. Science 1995; 268: 884–886.
Takaoka A et al. Suppression of invasive properties of colon cancer cells by a metastasis suppressor KAIl gene. Oncogene 1998; 16: 1443–1453.
Jackson P, Kingsley E, Russell PJ . Inverse correlation between KAI1 mRNA levels and invasive behaviour in bladder cancer cell lines. Cancer Lett 2000; 156: 16–176.
Yang JL et al. Invasion and metastasis correlate with down-regulation of KAI1 expression in human colon cancer cell lines. GI Cancer 2001; 3: 313–322.
Yang XH et al. Over-expression of KAI1 suppresses in vitro invasiveness and in vivo metastasis in breast cancer cells. Cancer Res 2001; 61: 5284–5288.
Adachi M et al. Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res 1996; 56: 1751–1755.
Ow KT et al. Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer. J Pathol 2000; 191: 39–47.
Guo XZ et al. KAI1, a new metastasis suppressor gene, is reduced in metastatic hepatocellular carcinoma. Hepatology 1998; 28: 1481–1488.
Yang XH et al. KAI1 protein is down-regulated during the progression of human breast cancer. Clin Cancer Res 2000; 6: 3424–3429.
Lombardi DP et al. Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res 1999; 59: 5724–5731.
Schindl M, Birner P, Breitenecker G, Oberhuber G . Downregulation of KAI1 metastasis suppressor protein is associated with a dismal prognosis in epithelial ovarian cancer. Gynecol Oncol 2001; 83: 244–248.
Tozawa K et al. KAI1 expression can be a predictor of Stage A prostate cancer progression. Prost Cancer Prost Dis 2001; 4: 150–153.
Huang CI et al. Correlation of reduction in MRP/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol 1998; 153: 973–983.
Bouras T, Frauman AE . Expression of the prostate cancer metastasis suppressor KAI1 in primary prostate cancers: a biphasic relationship with tumour grade. J Pathol 1999; 188: 382–388.
Dong JT et al. Down-regulation of the KAI1 metastasis gene during the progression of human prostatic cancer infrequently involves gene mutation of allelic loss. Cancer Res 1996; 56: 4387–4390.
Ueda T et al. Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. Am J Pathol 1996; 149: 1435–1440.
Ward JE et al. Expression of KAI1 in paraffin-embedded normal, hyperplastic and neoplastic prostate and prostate carcinoma cell lines. Pathol Int 1998; 48: 87–92.
Franks LM . The spread of prostate cancer. J Pathol Bacteriol 1956; 72: 603–611.
Zetter BR . The cellular basis of site-specific tumor metastases. N Engl Med J 1990; 32: 605–612.
Dong JT, Isaacs WB, Barrett JC, Isaacs JT . Genomic organisation of the human KAI1 metastasis-suppressor gene. Genomics 1997; 41: 25–32.
Jackson P et al. Methylation of a CpG island within the promoter region of the KAI1 metastasis suppressor gene is not responsible for down-regulation of KAI1 expression in invasive cancer or cancer cell lines. Cancer Lett 2000; 157: 169–176.
Liu FS et al. Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma. Gynecol Oncol 2000; 78: 10–15.
Miyazaki T et al. Mutation and expression of the metastasis suppressor gene KAI1 in esophageal squamous cell carcinoma. Cancer 2000; 89: 955–962.
Mashimo T et al. The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc Natl Acad Sci USA 1998; 95: 11 307–11 311.
Stapleton AMF et al. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 1997; 3: 1389–1397.
Berney CR et al. Evidence for post-transcriptional down-regulation of the apoptosis-related gene bcl-2 in human colo-rectal cancer. J Pathol 2000; 191: 15–20.
Quinn DI et al. Prognostic significance of p53 nuclear accumulation in localised prostate cancer treated with radical prostatectomy. Cancer Res 2000; 60: 1585–1594.
Downing SD, Jackson P, Russell PJ . Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression: a review of the evidence. Urol Oncol 2001; 6: 103–110.
Mashimo T et al. Activation of the tumor metastasis suppressor gene, KAI1, by etoposide is mediated by p53 and c-jun gens. Biochem Biophys Res Commun 2000; 274: 370–376.
Jackson P et al. Relationship between expression of the KAI1 gene mRNA levels and p53 status in human bladder and prostate cancer cell lines. Urol Oncol 2002; 7: 99–104.
Duriez C et al. Absence of p53-dependent induction of the metastatic suppressor KAI1 gene after DNA damage. Oncogene 2000; 19: 2461–2464.
Jackson P, Puisieux A . Is the KAI1 metastasis suppressor gene a cellular target of p53? A review of current evidence. Biochem Biophys Res Commun 2000; 278: 499–502.
Schindl M et al. Impact of human papillomavirus infection on the expression of the KAI1 metastasis suppressor protein in invasive cervical cancer. Cancer Lett 2001; 162: 261–266.
Jackson P et al. p53-dependent activation of the mouse MCK gene promoter: identification of a novel p53-responsive sequence and evidence for co-operation between distinct p53 binding sites. Gene Expression 1995; 5: 19–33.
Acknowledgements
The authors thank Drs Julie Brown and Sean Downing of the Oncology Research Centre for their help and advice during the preparation of this manuscript. We also thank St. Vincent's Campus Prostate Group and Dr. P. Stricker for contributing specimens.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jackson, P., Ow, K., Yardley, G. et al. Downregulation of KAI1 mRNA in localised prostate cancer and its bony metastases does not correlate with p53 overexpression. Prostate Cancer Prostatic Dis 6, 174–181 (2003). https://doi.org/10.1038/sj.pcan.4500634
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500634
Keywords
This article is cited by
-
Tetraspanin CD82: a suppressor of solid tumors and a modulator of membrane heterogeneity
Cancer and Metastasis Reviews (2015)
-
Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein
Cancer Gene Therapy (2010)
-
Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells
Oncogene (2009)
-
Metastasis Suppressors and Their Roles in Breast Carcinoma
Journal of Mammary Gland Biology and Neoplasia (2007)
-
KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells
Oncogene (2005)